Clinical Research Directory
Browse clinical research sites, groups, and studies.
Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer
Sponsor: Yanhong Deng
Summary
Surgery with integrated treatment for metastatic colorectal cancer (mCRC) has created a new clinical setting known as mCRC with no evidence of disease (NED). However, these patients have a high risk of developing persistent cancer. This study aimed to investigate the efficacy and safety of Tislelizumab combined with capecitabine as a maintenance treatment for patients with mCRC-NED.
Official title: Maintenance Tislelizumab Combined With Capecitabine to Treat Metastatic Colorectal Cancer With No Evidence of Disease
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
52
Start Date
2023-08-22
Completion Date
2027-11-30
Last Updated
2023-12-12
Healthy Volunteers
No
Conditions
Interventions
Tislelizumab + Capecitabine
Tislelizumab 200mg iv every 3 weeks, for 1 year after completion of perioperative chemotherapy. Capecitabine was given at a dose of 850 mg/m2 twice a day by mouth, 2 weeks on/ 1 week off, for 1 year after completion of perioperative chemotherapy.
Best supportive care
Best supportive care
Locations (1)
Gastrointestinal Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China